Acrivon Therapeutics, Inc. Common Stock (ACRV) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.87 (+10.00%), Market cap $0.07B, 52-week low–high $1.05 ~ $3.01.
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian canc
Financial statements, price targets, institutional (13F) holdings and related news for Acrivon Therapeutics, Inc. Common Stock are updated in real time on BlackAll Trade.
Acrivon Therapeutics, Inc. Common Stock trades at $1.87 (+10.00%). Real-time quotes and charts are available on BlackAll Trade.
Acrivon Therapeutics, Inc. Common Stock has a market cap of about $0.07B.
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by u